Photo of Jesse David Roberts, MD

Jesse David Roberts, MD

  • Director of Newborn Research, Mass General Hospital for Children
  • Associate Pediatrician
  • Associate Anesthesiologist





Anesthesia, Critical Care & Pain Medicine

Centers & Specialties

MassGeneral Hospital for Children

Clinical Interests
  • Neonatology
  • Pediatric anesthesia
  • Pulmonary hypertension
  • Molecular medicine
  • Bronchopulmonary dysplasia
  • Nitric oxide
Medical Education
  • MD, University of Rochester School of Medicine and Dentistry
  • Residency, Massachusetts General Hospital|Residency, UC San Diego Main Campus
  • Fellowship, Women and Infants Hospital/Care New England
Board Certifications
  • Anesthesiology
  • Pediatrics
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • OSW - Vermont
  • Private Health Care Systems (PHCS)
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group


The long-term goals of my laboratory are to explore the fundamental mechanisms of newborn lung injury and to develop novel therapies for pulmonary vascular disease.

Lung injury in children often causes abnormal pulmonary arterial vasoreactivity and muscularization. Through processes that are incompletely understood, many children with lung injury develop progressive and irreversible pulmonary hypertension, intra- and extra-pulmonary shunting of deoxygenated blood, and severe hypoxemia.

In early studies, we observed that low levels of inhaled NO rapidly cause pulmonary vasodilatation. Furthermore, the dilator effect of inhaled NO was limited to the lungs since it did not cause systemic vasodilatation. After evaluating the dose-response to inhaled NO in the laboratory and developing a safe NO delivery system, we performed the first clinical trials of inhaled NO in pediatric patients with pulmonary hypertension. Low levels of inhaled NO were observed to safely decrease hypoxemia and pulmonary hypertension in critically ill newborns with pulmonary vascular disease and intrapulmonary shunt. Subsequently, my laboratory led a prospective, randomized, placebo controlled, multicenter study that demonstrated that inhaled NO treatment decreases hypoxemia and the requirement for extracorporeal membrane oxygenation (ECMO) in newborns with pulmonary hypertension. These studies stimulated investigations of inhaled NO in the pediatric lung through out the world and were pivotal in the acceptance of inhaled NO by the Federal Drug Administration of the United States as a therapy for pulmonary hypertension and hypoxemia in newborns.

Research & Publications

Research Summary

Research Areas

  • Novel mechanisms and therapies for pulmonary vascular disease in pediatric patients.
  • Role of inhaled nitric oxide (NO) gas in preventing newborn lung diseases.
  • Molecular mechanisms through which NO and cGMP regulate vascular smooth muscle cell differentiation and proliferation.   

Description of Research

My research focuses on discovering novel mechanisms and therapies for pulmonary
vascular disease in pediatric patients. My team's current work is directed at:
  • examining the molecular mechanisms through which NO and cGMP regulate vascular smooth muscle cell proliferation and differentiation
  • examining how cytokine neutralization may protect NO and cGMP signaling in models of pediatric chronic lung disease
  • identifying novel signaling systems that contribute to the pathobiology of pulmonary hypertension in newborns and infants
My lab is in the Cardiovascular Research Center of Mass General Hospital.
Over 60 publications


Anesthesia, Critical Care and Pain Medicine
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-724-3104
Fax: 617-726-9346

Back to Top